基于根治性前列腺切除术后不良病理对中危前列腺癌主动监测风险进行亚型分类
该研究比较低危与有利中危前列腺癌患者根治性前列腺切除术后不良病理(GG≥3/pT3b/pN1)的发生率及生存影响。低危患者不良病理率为6.8%,中危GG2患者为20.8%(RR 3.06)。有利中危患者不良病理风险是低危的三倍,导致总生存更差。
要点
- 有利中危前列腺癌患者术后不良病理风险约为低危患者的3倍。
- 中危患者可进一步分为1型和2型,2型不良病理风险更高。
- 有利中危患者因不良病理导致调整后总生存劣于低危患者。
核心结论
- 有利中危前列腺癌患者根治性前列腺切除术后不良病理发生率是低危患者的3倍,并导致更差的总生存。
- 中危患者宜分为1型和2型,因无任何亚型的不良病理结局与低危患者相似。
研究设计与样本
- 基于美国国家癌症数据库2009至2013年接受根治性前列腺切除术的前列腺癌患者的比较队列研究。
- 主要终点为不良病理,定义为Grade Group 3或以上/pT3b/pN1。
- 评估了多种有利中危定义,包括纪念斯隆凯特琳癌症中心定义(Grade Group 2或以下且仅1个中危因素:GG2/cT2b/PSA 10-20 ng/ml),定义为1型中危,其余中危为2型中危。
主要发现
- 低危患者不良病理率为6.8%(3,519/51,688),中危GG2患者为20.8%(8,888/42,720),RR 3.06(95% CI 2.95-3.17,p<0.001)。
- 按PSA和体积分层对绝对率影响甚微。
- 2型中危不良病理风险更高(RR 8.52,95% CI 8.23-8.82,p<0.001),1型中危风险更低(RR 2.00,95% CI 1.86-2.16,p<0.001)。
- 调整模型中,有利中危患者因不良病理导致总生存劣于低危患者。
关键数值与推荐
- 不良病理定义为Grade Group 3或以上/pT3b/pN1。
- 1型中危定义为纪念斯隆凯特琳癌症中心标准:Grade Group 2或以下且仅1个中危因素(GG2/cT2b/PSA 10-20 ng/ml)。
- 其余中危患者归类为2型中危。
临床怎么用
- 对有利中危前列腺癌患者考虑主动监测时,应告知其术后不良病理风险约为低危患者的3倍。
- 中危患者可进一步亚型分类以辅助风险分层,2型中危不良病理风险更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intermediate risk prostate cancer is a heterogenous classification with favorable proposed criteria based on men treated with radiation therapy. However, there is uncertain application to active surveillance. We quantified the rate of adverse surgical pathology and implications for survival in patients at favorable intermediate risk compared to those with low risk prostate cancer. MATERIALS AND METHODS: We performed a comparative cohort study of men with prostate cancer from 2009 to 2013 in the National Cancer Database who underwent radical prostatectomy. The study primary end point was adverse pathology, defined as Grade Group 3 or greater/pT3b/pN1. Various favorable intermediate risk definitions were evaluated, including the Memorial Sloan Kettering Cancer Center definition of Grade Group 2 or less with only 1 intermediate risk factor (Grade Group 2/cT2b/prostate specific antigen 10 to 20 ng/ml), which we defined as type 1 intermediate risk. The remaining patients at intermediate risk were classified as type 2 intermediate risk. Log binomial, logistic and Cox proportional hazards regression models were applied. RESULTS: Adverse pathological findings were noted in 3,519 of the 51,688 patients (6.8%) at low risk and 8,888 of the 42,720 Grade Group 2 patients (20.8%) at intermediate risk (RR 3.06, 95% CI 2.95-3.17, p <0.001). Stratification by prostate specific antigen and volume minimally impacted the absolute rate. Results were similar for the Memorial Sloan Kettering Cancer Center definition (type 1 intermediate risk). Type 2 intermediate risk led to a greater risk of adverse pathology (RR 8.52, 8.23-8.82, p <0.001) and Grade Group 1 intermediate risk led to lower risk (RR 2.00, 1.86-2.16, p <0.001). Patients at favorable intermediate risk had worse overall survival than patients at low risk in adjusted models due to adverse pathology. CONCLUSIONS: Adverse pathology at radical prostatectomy was observed at a threefold higher rate in patients classified at favorable intermediate risk compared to low risk, leading to worse overall survival. Men at intermediate risk may be better classified as types 1 and 2 since none showed pathological outcomes similar to those of men at low risk.
引用
- Patel HD, Gupta M, Tosoian JJ, et al. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy. J Urol. 2018. PMID: 29673946. doi:10.1016/j.juro.2018.04.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。